To view or add a comment, sign in Struggling with GLP-1 therapy side effects
Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial
doi: 10.3389/fnmol.2021.793004 Received 11 October 2021 Accepted 29 November 2021 Published 17 December 2021 Volume 14 - 2021 Edited by Inmaculada Segura, Ludwig Maximilian University of Munich, Germany Reviewed by Jong-Woo Sohn, Korea Advanced Institute of Science and Technology, South Korea
GLP-1 directly activates POMC/CART neurons and indirectly inhibits, via GABAergic transmission, the neuropeptide Y/agouti-related peptide (NPY/AgRP) neurons, which collectively results in signals that reduce food intake
For current information, visit the official site